ACP6

Across TCGA pan-cancer cohorts, ACP6 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACP6 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher ACP6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ACP6 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRC, OV, and HNSC are the cancer types where ACP6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.123	0.805	<.001	42	view →
OV	DFS	Median	II,III,IV	0.235	0.542	.006	18	view →
HNSC	OS	Median	All	0.222	0.751	.007	12	view →
UCEC	DFS	Median	All	0.953	0.629	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ACP6–KIRC (OS)

Open the KIRC breakdown →